title: Frailty and Transplantation.
abstract: Consequences of aging are gaining clinical relevance. In transplantation, aging and immunosenescence impact treatment and outcomes. The impact of aging, however, will critically depend on distinguishing healthy, chronological aging from biological aging that may result into frailty. Approximately 15% of individuals older than 65 years are frail, and it is expected that this condition will gain more clinical relevance with an expected increase to greater than 20% over the next 5 years. Clearly, frailty impacts various general aspects of health care and organ transplantation in particular including patient selection, waitlist management and treatment after transplantation. In general, frailty has been characterized by a compromised physiological reserve and an augmented vulnerability. In comparison to healthy aging, inflammatory markers and cytokines are increased in frail older adults. Thus, modifications of the immune response, in addition to physical limitations and changes of metabolism, are likely to impact outcomes after transplantation. Here, we provide a risk assessment of frailty at the time of transplant evaluation and review effects on outcomes and recovery after transplantation. Moreover, we summarize our current understanding of the pathophysiology of frailty and consequences on immune responses and metabolism.
authors.affiliation: 1 Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 2 Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands. 3 Division of Transplant Surgery, Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, The Netherlands. 4 Institute of Transplant Immunology, Hannover Medical School, Hannover, Lower Saxony, Germany. 5 Department of Visceral, Transplantation, Thoracic and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany. 6 Department of Urology, Osaka Medical College, Takatsuki, Osaka, Japan.
authors.forename: Leonie
authors.initials: L
authors.lastname: Exterkate
authors.forename: Bendix R
authors.initials: BR
authors.lastname: Slegtenhorst
authors.forename: Matthias
authors.initials: M
authors.lastname: Kelm
authors.forename: Midas
authors.initials: M
authors.lastname: Seyda
authors.forename: Jeroen M
authors.initials: JM
authors.lastname: Schuitenmaker
authors.forename: Markus
authors.initials: M
authors.lastname: Quante
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Uehara
authors.forename: Abdala
authors.initials: A
authors.lastname: El Khal
authors.forename: Stefan G
authors.initials: SG
authors.lastname: Tullius
mesh_terms: D000367:Age Factors; D000368:Aged; D000375:Aging / Q000276:immunology / Q000378:metabolism / Q000523:psychology; D003071:Cognition; D005260:Female; D016330:Frail Elderly / Q000523:psychology; D015577:Geriatric Assessment; D006304:Health Status; D006801:Humans; D000068884:Immunosenescence; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D010359:Patient Readmission; D018579:Patient Selection; D011183:Postoperative Complications / Q000209:etiology / Q000628:therapy; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology / Q000601:surgery*; D018570:Risk Assessment; D012307:Risk Factors; D066027:Transplant Recipients; D016896:Treatment Outcome